The investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy, BeiGene, the company manufacturing the agent, has announced.